Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2017-04-21
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/
Dexamethasone will prolong the time before myeloma worsens [progression free survival (PFS)].